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Natural killer (NK) cells mediate innate immune re-
sponses against hazardous cells and are particularly
important for the control of human cytomegalovirus
(HCMV). NKG2D is a key NK activating receptor
that recognizes a family of stress-induced ligands,
including MICA, MICB, and ULBP1-6. Notably, most
of these ligands are targeted by HCMV proteins and
a miRNA to prevent the killing of infected cells by
NK cells. A particular highly prevalent MICA allele,
MICA*008, is considered to be an HCMV-resistant
‘‘escape variant’’ that confers advantage to human
NK cells in recognizing infected cells. However,
here we show that HCMV uses its viral glycoprotein
US9 to specifically target MICA*008 and thus es-
capes NKG2D attack. The finding that HCMV evolved
a protein dedicated to countering a single host
allele illustrates the dynamic co-evolution of host
and pathogen.INTRODUCTION
Human cytomegalovirus (HCMV) is amember of the Betaherpes-
virus family, possessing a complex dsDNA genome that en-
codes hundreds of genes (Stern-Ginossar et al., 2012). The
majority of the population is latently infected with HCMV with
no overt symptoms, yet HCMV can cause significant morbidity
and mortality in immunosuppressed individuals and in congeni-
tally infected neonates (Griffiths, 2012).
Natural killer (NK) cells are innate immune lymphocytes named
for their ability to kill cancer cells without prior sensitization
(Cheent and Khakoo, 2009). NK cells are especially important968 Cell Reports 10, 968–982, February 17, 2015 ª2015 The Authorsin combating viral infections in general and HCMV in particular,
and consequently, NK-deficient patients succumb to lethal
HCMV infections (Orange, 2013). NK cell activity is governed
by integrating signals from a panel of activating and inhibitory re-
ceptors (Cheent and Khakoo, 2009). One of the key activating NK
receptors is NKG2D, a C-type lectin that recognizes a family
of major histocompatibility complex (MHC)-like stress-induced
ligands: MHC class I polypeptide-related sequences (MIC) A
and B, and UL16 binding proteins (ULBP) 1–6 (Ferna´ndez-Mes-
sina et al., 2012). NKG2D ligands are usually absent from normal
cells, but different forms of stress such as DNA damage and viral
infection can induce their expression, leading to recognition and
elimination of hazardous cells (Ferna´ndez-Messina et al., 2012).
HCMV employs numerous strategies to avoid NK cell recogni-
tion (Wilkinson et al., 2008), and many among them target the
stress-induced ligands. Specifically, the viral protein UL16 se-
questers MICB and ULBP1/2/6 inside infected cells, whereas
the viral protein UL142 sequesters MICA and ULBP3 (Halenius
et al., 2014; Slavuljica et al., 2011). In addition, the viral glycopro-
teins US18 and US20 were recently shown to target MICA to
lysosomal degradation (Fielding et al., 2014). Finally, the miRNA
HCMV-miR-UL112 targetsMICBmRNA to reduceMICB expres-
sion (Stern-Ginossar et al., 2007).
MICA is the most polymorphic NKG2D ligand with >80 known
alleles (Ferna´ndez-Messina et al., 2012). A particular allele,
MICA*008, is resistant to various HCMV immune evasion strate-
gies: UL142 does not target it (Ashiru et al., 2009; Chalupny
et al., 2006), and it is not downregulated upon infection with
HCMV strain AD169VarS (Zou et al., 2005). Unlike most MICA al-
leles, MICA*008 is truncated and lacks a cytoplasmic tail due to a
frameshiftmutation in its transmembrane (TM) domain.MICA*008
was recently shown to be glycosylphosphatidylinositol (GPI)
anchored, unlike full-length MICA alleles. The GPI-anchoring
process is very slow and ismediated by a nonstandard, as yet un-
known, pathway (Ashiru et al., 2013).
MICA*008 is the most prevalent allele in most studied popula-
tions, comprising up to 53% of all alleles (Petersdorf et al., 1999;
Zhang et al., 2001). These findings gave rise to the hypothesis
that MICA*008 may confer resistance to HCMV infection, and
its high frequency is the result of positive selective pressure ex-
erted by HCMV (Slavuljica et al., 2011; Wilkinson et al., 2008).
TheUS2-US11 region of the HCMV genome encodes eight TM
glycoproteins of limited homology not essential for HCMV repli-
cation in vitro (Huber et al., 2002; Jones and Muzithras, 1991,
1992). Several of these proteins target the MHC pathways, while
the function of three others (US7, US8, and US9) remained unde-
termined (Huber et al., 2002).
Here, we show that US9 selectively downregulates MICA*008,
previously thought resistant to HCMV manipulation, to escape
NKG2D-mediated attack by NK cells.
RESULTS
US9 Selectively Downregulates the Truncated
Allele MICA*008
To test whether US7, US8, and US9 modulate NK cell function,
we overexpressed them in various cells lines. Because anti-
bodies directed against these HCMV proteins are unavailable,
the three proteins were fused to HIS or HA tags. Of the three
tested proteins, US7 and US8 had no effect on the expression
of the following ligands: MHC class I, b2 m, HLA-E, PVR, Nec-
tin-2, ICAM1, CCM1, MICA, MICB, ULBP1, ULBP2/5/6, and
ULBP3 (data not shown). We therefore did not study US7 and
US8 any further.
US9 was previously reported to be ER resident (Huber et al.,
2002; Mandic et al., 2009). Immunofluorescence revealed a
high degree of US9 localization to the ER with no discernible
surface expression (Figure S1A). Expression of US9 was also
verified by western blotting. As previously shown (Huber et al.,
2002), two US9 products, ascribed to different glycosylations,
were detected (Figure 1A).
We next tested US9’s effect on the surface expression of
various NK cell ligands. Notably, expression of US9 in 293T
and in HeLa cells abolished MICA expression compared with
its level in empty-vector (EV)-transduced controls (Figure 1B).
A moderate downregulation of MICA was observed in MCC13
cells, and no MICA downregulation was observed in A549 and
in HCT116 cells (Figure 1B). The US9-mediated downregulation
of MICA was selective, as no difference was observed in MHC
class I and MICB expression (Figure 1B) or in the expression of
other stress-induced ligands (Figure S1B).
The selective, cell-type-dependent downregulation of MICA
was unexpected. However, because it was previously shown
that MICA*008 is resistant to HCMV manipulation (Ashiru et al.,
2009; Chalupny et al., 2006; Zou et al., 2005), we speculated
that the US9-resistant cells probably express this allele. To our
surprise, 293T and HeLa cells were in fact previously shown to
be homozygous for MICA*008, whereas HCT116 cells were
shown to express full-length MICA alleles (McSharry et al.,
2008; Zhang et al., 2001).
We therefore speculated that US9 specifically targets the trun-
cated MICA*008 allele, and to test this, we genotyped the A549
and MCC13 cell lines, which had never been typed. Importantly,Cewe observed a strict correlation between MICA genotype and
US9 effect: in the heterozygous MCC13 cells (MICA*008/
*009:02), a moderate effect on MICA was observed, and in
A549 cells (MICA*001/*004), no effect on MICA expression was
observed (Figure 1B). Table S1 summarizes the MICA genotype
and expression of the cell lines used in this study.
The main differences between full-length MICA alleles and
MICA*008 are shown in Figure 1C. A G-nucleotide insertion at
position 952 located in the middle of the MICA*008 TM domain
causes a frameshift. This results in an alternate reading frame
of 15 amino acids (AAs), followed by a premature stop codon.
Post-transcriptional Regulation of MICA*008
Expression by US9
To determine the mechanism by which US9 downregulates
MICA*008, we performed western blots in the presence or in
the absence of US9. It should be noted that MICA is a highly gly-
cosylated protein, which migrates in ‘‘smears’’ due to variable
carbohydrate composition (Ashiru et al., 2013). Different expo-
sures of the same gel are shown due to varyingMICA expression
in the cell lines. A single exposure of the same gel is shown in Fig-
ure S2A.Western blots confirmed the cell line genotypes since in
the absence of US9, the MICA*008 homozygous cell lines 293T
and HeLa express MICA at a size of roughly 60 kDa; the
HCT116 cell line, which has full-length alleles, expresses MICA
at a size of about 75–100 kDa, while the heterozygous line
MCC13 has protein bands of both 75 and 60 kDa (Figure 2A).
In the presence of US9, a considerable reduction in MICA*008
level in 293T and HeLa cells was observed (Figure 2A, quantified
in Figure 2B). In contrast, in HCT116 cells, no reduction in MICA
level was observed. Notably, in the heterozygous MCC13 cell
line, only MICA*008 was affected (Figure 2A, quantified in Fig-
ure 2B). We validated these results by utilizing HeLa and
HCT116 cells transduced with US8 as control (Figure S2B).
These results exclude the possibility that US9 sequesters
MICA*008 inside cells. To investigate whether US9 affects
MICA*008 mRNA quantity, we performed qRT-PCR on cDNA
extracted from HeLa cells (MICA*008 homozygous) and from
MCC13 cells (heterozygous) and observed no significant dif-
ferences (Figure 2C). This suggests that US9 acts post-
transcriptionally.
We confirmed these results in RKO cells, which express very
low levels of the full-length allele MICA*007:01 (Table S1; Figures
2D and S2C). We transduced RKO cells either with the full-length
allele MICA*004 or with MICA*008, fused to an N-terminal HA
tag, and then co-transduced these cells with EV or with US9
fused to a HIS tag. MICA*008 levels were substantially reduced
in US9-expressing cells compared with the EV control (Fig-
ure 2D), while no difference was apparent in MICA*004 expres-
sion. We validated these results by blotting with an a-HA tag
antibody (Figure 2E) and by comparing to EV, US7, and US8-ex-
pressing controls (Figure S2C). Immunofluorescent imaging of
the RKO transfectants showed that MICA*008 indeed almost
vanished from the US9-expressing cells (Figure 2F).
US9 Targets MICA*008 to Proteasomal Degradation
Intriguingly, in RKO transfectants, all MICA alleles migrated at a
higher molecular weight, MICA*004 at 100 kDa and MICA*008ll Reports 10, 968–982, February 17, 2015 ª2015 The Authors 969
Figure 1. US9 Expression Specifically Reduces MICA Surface Expression in Certain Cell Lines
(A) Western blot of US9 expression in the indicated cells, transduced either with an EV or with tagged US9, using the indicated antibodies.
(B) FACS staining for MICA, MICB, and MHC class I expression (top, middle, and bottom histograms, respectively) in cell lines transduced with an EV (black
histograms) or with US9 (red histograms). Gray-filled histograms represent secondary antibody staining. Representative of three independent experiments.
(C) Multiple sequence alignment conducted using the IMGT/HLA database (http://www.ebi.ac.uk/ipd/imgt/hla/) of the TM and cytoplasmic domain of the MICA
alleles present in the cell lines described in (B). Red highlights sequences unique for MICA*008. The gray square marks the TM region.
See also Figure S1.at 70 kDa, probably due to altered glycosylations. Concur-
rently, another MICA*008 form of 60 kDa could be detected
in RKO cells, and this form of the protein was unaffected by
US9 (indicated by an arrow; Figures 2D, 2E, and S2C), suggest-
ing that some forms of MICA*008 may be US9 resistant and that
US9 acts post-translationally.
To analyze the mechanism by which US9 affects MICA*008,
we digested with endoglycosidaseH (endoH) and PNGaseF ly-
sates obtained from HeLa cells (endogenous MICA*008) and970 Cell Reports 10, 968–982, February 17, 2015 ª2015 The Authorsfrom RKO-MICA*008-HA transfectants (Figures 3A–3D, respec-
tively) in the presence of EV or US9. In HeLa-EV cells (Figure 3A),
most MICA*008 was endoH resistant. Deglycosylation with
PNGaseF revealed two distinct bands: a band of 37 kDa, re-
presenting the endoH sensitive, non-GPI-anchored form of
MICA*008, and a band of about 34 kDa, representing the endoH
resistant, GPI-anchored formofMICA*008 (Ashiru et al., 2013). In
contrast, in HeLa-US9, only the endoH-sensitive, 37-kDa form of
MICA*008 remained (Figure 3B).
Figure 2. US9 Regulates MICA Post-transcriptionally
(A) Lysates obtained from the indicated cells expressing either an EV or US9 were blotted using a-MICA. a-PP2AC served as loading control. Shown are different
exposures of the same gel due to differences in MICA expression levels. A single exposure can be seen in Figure S2A.
(B) Quantification of the relative MICA protein levels shown in (A): protein quantity was normalized, and then the ratio of MICA levels for each cell line was
calculated as follows: (level in US9-expressing cells)/(level in EV-expressing cells).
(C) qRT-PCR was performed in triplicate using cDNA from the indicated cell lines and MICA-specific primers. The results were normalized, and then the fold
change of the mRNA level was calculated for each experiment as follows: (level in US9-expressing cells)/(level in EV-expressing cells). Error bars show SEM for
two to four independent experiments; p value was calculated using a single-sample t test against a hypothetical mean of 1. N.S., nonsignificant.
(D and E) Western blot using the indicated antibodies was performed on lysates obtained from RKO cells transduced with an EV, with MICA*004-HA, or with
MICA*008-HA and co-transduced with an EV or with US9. a-PP2AC served as loading control. The arrows indicate the immature form of MICA*008.
(F) RKO cells as in (D) and (E) were stained with an a-MICA and an a-HIS tag antibodies, and images were captured by confocal microscopy. The average
correlation coefficient for colocalization between the two antibodies is indicated, calculated for >30 cells.
See also Figure S2.
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Figure 3. US9 Targets MICA*008 to Proteasomal Degradation
(A–D) HeLa cells expressing EV (A) or US9 (B) or RKOMICA*008-HA cells co-transduced with EV (C) or US9 (D) were lysed, and the lysates were left untreated or
digested with endoH or with PNGaseF (marked N, H, and F, respectively) and then blotted using the indicated antibodies. Arrows indicate MICA forms with and
without carbohydrates (CH+/). a-Vinculin served as loading control.
(E and F) HeLa cells expressing EV (E) or US9 (F) were mock treated or were treated with the following inhibitors: the lysosomal protease inhibitor LEU (100 mg/ml),
the lysosomal acidification inhibitor CCMA (20 nM), the irreversible proteasome inhibitor EPX (0.5 mM), the reversible proteasome inhibitor MG132 (10 mM), or the
reversible proteasome inhibitor BTZ (10 mM). Following 16 hr of treatment, the cells were lysed and blotted using a-MICA and a-HIS antibodies. a-Vinculin served
as loading control. Arrows indicate MICA forms with and without carbohydrates (CH+/).
(G and H) HeLa cells expressing EV (G) or US9 (H) were left untreated (N) or were incubated for 8 hr with the translation inhibitor CHX (100 mg/ml) in combination
with mock treatment or with the following inhibitors: LEU (100 mg/ml), CCM A (40 nM), EPX (40 mM), or BTZ (300 mM). Following treatment, cells were lysed and
blotted with a-MICA. a-Vinculin served as control. Arrows indicate MICA forms with and without carbohydrates (CH+/). Dashed vertical lines indicate different
gel segments.
See also Figure S3.
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In RKO cells, deglycosylation revealed that the highly glycosy-
lated band that migrates at 70 kDa corresponds to the mature,
GPI-anchored 34-kDa form ofMICA, whereas the60-kDaUS9-
resistant band corresponds to the endoH-sensitive, 37-kDa form
of MICA. Similar to what was seen in HeLa cells, only the 37-kDa
form of MICA*008 could be detected in the presence of US9.
Following PNGaseF treatment, it was also possible to detect a
fainter band of 42 kDa, which represents the deglycosylated
native full-length allele expressed by RKO cells (Figures 3C
and 3D).
These observations suggest that US9 does not act on
MICA*008 while it is in its non-GPI-anchored form, but still tar-
gets it prior to its egress from the ER, since no endoH-resistant
forms of MICA*008 could be detected in US9-expressing cells.
Along with the fact that US9 is ER resident (Figure S1A), this
implied that US9 acts by recruiting ER-associated degradation
(ERAD) complexes, which dislocate proteins from the ER lumen
to the cytosol, where the proteins are deglycosylated and
degraded by the proteasome (Loureiro and Ploegh, 2006).
To test this hypothesis, HeLa cells expressing either EV (Fig-
ure 3E) or US9 (Figure 3F) were treated for 16 hr with several
inhibitors of lysosomal or of proteasomal degradation or with
an appropriate mock treatment and then lysed and immunoblot-
ted to find whether any of these treatments would increase
MICA*008 levels in US9-expressing cells. Prolonged treatments
were required to show an effect, presumably due to MICA*008’s
slow maturation kinetics (Ashiru et al., 2013). In EV-expressing
HeLa cells (Figure 3E), the proteasome inhibitors, as well as con-
canamycin A (CCM A), a lysosomal acidification inhibitor, in-
duced MICA expression. All inhibitors also upregulated MICA
in US9-expressing cells (Figure 3F). However, we cannot discern
whether it is due to MICA induction (which may differ in its extent
between EV- and US9-expressing cells) or due to inhibition of
MICA degradation. Nevertheless, in the US9-expressing cells,
a smear of MICA*008 forms of sizes down to 37 kDa (the size
of the deglycosylated non-GPI-anchored form of MICA*008)
appeared following treatment with the proteasome inhibitors ep-
oxomicin (EPX), bortezomib (BTZ), and MG132 (Figure 3F, indi-
cated by arrows). We hypothesized that these forms represent
deglycosylated cytosolic degradation intermediates, reminis-
cent of MHC class I heavy chain degradation by US2. In another
intriguing parallel to US2, US9 itself is subject to proteasomal
degradation, since its levels are increased in the presence of pro-
teasome inhibitors (Figure 3F) (Wiertz et al., 1996).
To prevent interference from MICA induction, we utilized
cycloheximide (CHX) chase, which isolates protein degradation
rate. We treated HeLa-EV (Figure 3G) or HeLa-US9 (Figure 3H)
cells with inhibitors of proteasomal or lysosomal degradation,
in combination with CHX, for 8 hr. This treatment prevented
the induction of MICA*008, and importantly, in US9-expressing
cells treated with proteasome inhibitors, 37-kDa degradation in-
termediates of MICA*008 appeared again (Figure 3H, arrow). No
effect was observed in EV-expressing cells (Figure 3G) or for
lysosomal inhibitors.
We validated these results by performing an 8-hr CHX chase in
RKO-MICA*008-HA transfectants, which co-express EV (Fig-
ure S3A) or US9 (Figure S3B) in the presence of different doses
of proteasome and lysosome inhibitors. As expected, the quan-Cetity of the 60-kDa immature form of MICA was greatly reduced
following prolonged CHX treatment in EV and US9-expressing
cells. In US9-expressing cells (Figure S3B), this reduction was
partially rescued only by proteasome inhibitors treatment, which
also led to the dose-dependent appearance of 37-kDa degrada-
tion intermediates of MICA*008 (Figure S3B, arrows). In contrast,
the inhibitors did not affect EV-expressing cells (Figure S3A).
Because the reduction in the 60-kDa MICA form quantity
was mitigated by proteasome inhibitors in CHX-treated, RKO-
MICA*008-HA US9-expressing cells, we wanted to study the
composition and maturation status of this form following protea-
some inhibitor treatment. To this end, RKO-MICA*008-HA cells
expressing EV (Figure S3C) or US9 (Figure S3D) were left un-
treated or were treated with a combination of CHX and DMSO
(mock) or with a combination of CHX and proteasome inhibitor
EPX. Cells were lysed, and lysates were untreated or digested
with endoH or PNGaseF. Results revealed that the 37-kDa
non-GPI-anchored, endoH-sensitive form of MICA*008 is in-
creased in quantity following EPX treatment in US9-expressing
cells (Figure S3D), in accordancewith the hypothesis that it is tar-
geted by US9 to proteasomal degradation.
Specific Features of MICA*008, Correlated with
Noncanonical GPI Anchoring, Are Required for
US9-Mediated Downregulation
MICA*008 has two distinguishing features compared with full-
length alleles: a unique 15-AA sequence in the TM region and
an absent cytoplasmic domain. To determine which feature is
important for the specific targeting of MICA*008 by US9, we
generated several mutations in the full-length MICA*004 protein
(Figure 4A) and examined which of these would recapitulate the
MICA*008 phenotype upon co-expression with US9. For these
experiments, we again used RKO cells transfected with different
MICA alleles co-expressing an EV or US9. The native full-length
MICA allele of RKO cells was undetected at the cell surface (Fig-
ure 4B, left-most histogram). In agreement with our aforemen-
tioned western blot results (Figures 2D and 2E), US9 did not
affect the surface expression of the full-length allele MICA*004-
HA but substantially reduced the levels of MICA*008-HA as as-
sayed by fluorescence-activated cell sorting (FACS) staining
with a-MICA antibody (Figure 4B) and a-HA tag antibody (Fig-
ure S4A). Next, we introduced a G-insertion mutation (character-
istic of MICA*008), which leads to an altered reading frame of 15
AA and a premature stop codon (Figure 4A) into MICA*004-HA.
The resultant mutant, MICA*004-G-ins-HA, still differs from
MICA*008 in extracellular domain polymorphisms. Despite this,
MICA*004-G-ins-HA was robustly downregulated by US9 (Fig-
ures 4B and S4A).
To testwhether the absence of the cytoplasmic tail inMICA*008
is responsible for the US9-mediated downregulation, a premature
stop codon was introduced in MICA*004 (MICA*004-stop-HA) at
the end of the TM domain, but without the G-insertion mutation
(Figure 4A). The resultant MICA*004-stop-HA protein was not
downregulated by US9 (Figures 4B and S4A). We then tested
whether the 15-AA sequencewas itself sufficient for US9 recogni-
tion and generated a MICA*004 protein, namedMICA*004-Dmut-
HA, containing the 15 AAs found inMICA*008 and also including a
secondmutation to restore the reading frame and the cytoplasmicll Reports 10, 968–982, February 17, 2015 ª2015 The Authors 973
Figure 4. Specific Features of MICA*008, Correlated with Noncanonical GPI Anchoring, Are Required for US9-Mediated Downregulation
(A) Schematic representation of the MICAmutants and chimeric proteins used to identify which feature of MICA*008 is recognized by US9. The numbers indicate
the AA position of the TM and cytoplasmic domains and the positions of the G-insert mutation, where applicable. The AA positions stated are within the mature
protein, without taking into account the HA-tag sequence.
(B) FACS staining of MICA expression in RKO cells transducedwith theMICA proteins described in (A) and co-transduced with an empty vector (black histogram)
or with US9 (red histogram). Grey-filled histograms represent secondary antibody staining. Representative of three independent experiments.
(C) RKO cells transduced with the indicated proteins described in (A) were mock treated (black histograms) or treated (red histograms) with PI-PLC for 2 hr and
then stained for MICA (top histograms) and for ULBP3 (bottom histograms), as a positive control, and analyzed by flow cytometry. Grey-filled histograms
represent secondary antibody staining. Representative of two independent experiments.
(legend continued on next page)
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domain (Figure 4A). Because cells expressing MICA*004-Dmut-
HA were also unaffected by US9 (Figures 4B and S4A), we
concluded that both the absence of the cytoplasmic domain
and the presence of the unique 15-AA sequence in the TM region
of MICA*008 were necessary for US9 recognition. We verified our
results by immunoblotting lysates obtained from the same cells
described above. The absence of the mature form of MICA in
the presence of US9 was observed only in MICA*008-HA and in
MICA*004-G-ins-HA (Figure S4B), in accordancewith the flow cy-
tometry results.
To characterize whether the MICA mutants we created are
GPI-anchored, like MICA*008, we treated RKO cells transduced
with the various MICA constructs for 2 hr with phosphatidylino-
sitol-specific phospholipase C (PI-PLC), which specifically
cleaves GPI anchors, and then assessed the surface expression
of MICA. Staining for ULBP3, a GPI-anchored stress-induced
ligand, served as a positive control. Only MICA*008-HA and
MICA*004-G-ins-HA, the proteins susceptible to US9, were
also affected by PI-PLC treatment (Figure 4C). MICA surface
levels were reduced to a lesser extent by the treatment
compared with ULBP3, in accordance with previous results
regarding MICA*008, attributed to fatty-acid modifications of
the inositol moiety, which can hamper PI-PLC activity (Ashiru
et al., 2013). We verified this result by digesting lysates from
RKO cells transduced with the constructs described in Figure 4A
with PNGaseF. Only lysates from MICA*008-HA and MICA*004-
G-ins-HA migrated as two distinct bands, due to the addition of
the GPI moiety (Figure S4C).
Because our initial mutant screen revealed a correlation be-
tween the GPI-anchoring status of the MICA mutants and US9’s
ability to downregulate it, the question arose whether US9 might
simply recognize MICA, which undergoes GPI anchoring. To
address this, we generated an additional chimeric protein, named
MICA*008-ULBP3TM-HA, where we swapped MICA*008’s TM
domain with that of ULBP3, which contains a canonical GPI-
anchoring signal (Figure 4A). The resultant chimera was indeed
GPI anchored and susceptible to PI-PLC treatment like ULBP3 it-
self (Figure 4C), althoughwewere not able to observe two distinct
bands following PNGaseF digestion of MICA*008-ULBP3TM-HA
(Figure S4C), probably due to its faster maturation (Ferna´ndez-
Messina et al., 2012). Despite this, US9 did not downregulate
MICA*008-ULBP3TM-HA (Figures 4B and S4A), indicating that
some feature unique to MICA*008’s sequence or processing is
required for US9-mediated downregulation.
To confirm our conclusions, we swapped the TM domain of
MICB, which is not targeted by US9 (Figure 1B), with the TM
domain and the premature stop codon of MICA*008 (Figure 4D)
to create a chimeric protein termed MICB-mut. A full-length
MICB*002 allele, or the chimeric MICB-mut, was introduced
into 293T cells, which lack MICB surface expression (as seen
in Figure 4E), and the cells were then co-transduced with US9(D) Schematic representation of MICB and a mutated MICB. The numbers indicat
and the positions of the G-insert mutation, where applicable.
(E) a-MICB FACS staining of 293T cells transduced with an empty vector (left his
transduced with an empty vector (black histogram) or with US9 (red histogram). G
three independent experiments.
See also Figure S4.
Ceor with an EV. Low levels of MICB-mut-HA were expressed on
the cell surface, probably because of the swapping of its TM
domain. In contrast to the full-length MICB, which is unaffected
by US9, the chimeric MICB-mut was indeed susceptible to US9
(Figure 4E).
A Common US9 Variant with a C-Terminal Deletion
Is Functional against MICA*008
US9 is a highly conserved protein, apart from a variant present in
many HCMV strains, which lacks 15 AAs at its C terminus, result-
ing in a protein of 232 AAs instead of 247 AAs (Mandic et al.,
2009). Sequence alignment of representative US9 sequences
is shown in Figure S4D. We therefore wondered whether
the C-truncated 232-AA form of US9 is functional against
MICA*008.We inserted the C terminus deletion into the US9 pro-
tein of the TB40 strain and transduced it into RKO cells express-
ing MICA*004-HA or MICA*008-HA. Because the 232-AA variant
of US9 caused downregulation of MICA*008 similar to the full-
length variant of US9 and had no effect on MICA*004 (Fig-
ure S4E), we concluded that the C terminus of US9 is redundant
for its downregulation of MICA*008 and that this common variant
is fully functional.
US9 Downregulates MICA*008 during HCMV Infection
We next investigated whether US9 downregulates MICA*008
during HCMV infection. For this purpose, primary human fore-
skin fibroblasts (HFFs) were obtained from several healthy do-
nors and genotyped for MICA. The HFFs termed VH3 (Hengel
et al., 1995) were homozygous for MICA*008, while the HFFs
termed FLS1 (MICA*004/*009:01-*049; the latter alleles differ in
a single nucleotide in exon 6 and could not be distinguished)
were used as controls (Table S1). We generated amutant lacking
US9 (DUS9) on the background of HCMV strain AD169VarL,
which contains most of the ULb0 genomic region lacking in
AD169VarS, but harbors a UL140-UL144 deletion. Conse-
quently, this virus lacks UL142, which targetsMICA full-length al-
leles and ULBP3. We verified that US9 is not present in the viral
genome and is not expressed during infection (Figures 5A and
S5A, respectively).
Next, we infected the VH3 and FLS1 cells with the WT AD169-
VarL virus or with theDUS9 virus at anMOI of 2–4 and performed
time-course assays to track MICA surface expression from 0-hr
postinfection (hpi) to 72 hpi (Figure 5B). In the FLS1 HFF (full-
length alleles), MICA surface expression was progressively
downregulated until it was abrogated at 72 hpi, with no differ-
ence observed between the WT and DUS9 viruses. Importantly,
in the VH3 HFFs (MICA*008), the WT virus was able to downmo-
dulate MICA, while the DUS9 virus was significantly impaired in
MICA downregulation. At 72 hpi in the DUS9-infected VH3 cells,
MICA*008 expression was 2.5- to 3-fold higher than in theWT-in-
fected cells (Figure 5C). It is interesting to note that even the WTe the AA position within the mature protein of the TM and cytoplasmic domains
togram); with a WT MICB (middle histogram) or with MICB-mut (right) and co-
rey-filled histograms represent secondary antibody staining. Representative of
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Figure 5. US9 Reduces MICA*008 Surface Expression during HCMV Infection
(A) PCR using US9-specific primers on viral genomic DNA derived from AD169VarL and DUS9 virus, as annotated, resolved on acrylamide gel.
(B) FACS staining of HFF that were either UI or infected at an MOI of 2–4 with the indicated virus, at the indicated times post-infection. Black histogram, UI cells;
blue histogram, AD169varL; red histogram, DUS9. Grey-filled histograms represent isotype-matched control staining. Representative of three independent
experiments.
(C) Quantification of the relative median fluorescent intensity (MFI) of MICA for the 72 hpi staining in (B) was calculated as follows: background staining was
subtracted, and then the ratio (US9-expressing cells MFI)/(EV-expressing cells MFI) was calculated. Error bars show SEM for three independent experiments;
p value was calculated using a single-sample t test against a hypothetical mean of 1. *p < 0.05. N.S, nonsignificant.
(legend continued on next page)
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virus was unable to abolish MICA*008 expression, while it was
able to abolish MICA*004 expression. However, in this system,
MICA levels are also influenced by the induction of MICA expres-
sion caused by HCMV infection (Fielding et al., 2014; Zou et al.,
2005).
To validate these results in a system with constant MICA
levels, we next expressed different MICA alleles in primary
HFF. For these experiments, we used HFF termed FLS3, which
we observed in our screening to completely lack MICA protein
expression (Figures 5D and 7A), despite expressing MICA at
the mRNA level (Table S1). We transduced the FLS3 cells with
an EV, with MICA*004-HA or with MICA*008-HA, and infected
them with the WT or DUS9 viruses at an MOI of 2–4. At
72 hpi, in the MICA*004-HA-expressing transfectants, both
WT and DUS9 viruses were able to reduce MICA surface
expression to about 2%–3% of the uninfected (UI) level (Fig-
ure 5D, quantified in Figure 5E). Conversely, in the MICA*008-
HA transfectants, while MICA surface levels were decreased
in the DUS9-infected cells compared with the UI controls, they
were significantly higher than those in the WT-infected cells,
again resulting in a roughly 2.5-fold increase (Figure 5D, quanti-
fied in Figure 5E). Interestingly, the WT virus was once more
impaired in reducing MICA*008 expression, reducing its levels
only to about 15% of the original levels, and the absence of
US9 was not sufficient to completely restore MICA*008 expres-
sion, implying that other viral mechanisms also downregulate
this allele.
To confirm these results during infection with a viral strain,
which retains the clinical strain characteristics, we infected
FLS1, VH3, and FLS transfectants with TB40/E-pp150-GFP (Fig-
ure S5B). TB40/E behaved in the same way as the AD169VarL
virus: it completely downregulated full-length MICA alleles, but
not MICA*008. To validate the specificity of US9 during HCMV
infection, we stained the infected FLS1, VH3, and FLS3 transfec-
tant cells for additional stress-induced ligands at 72 hpi
(Figure S5C). As expected, both ULBP1 and ULBP2 were down-
regulated upon HCMV infection, whereas ULBP3 was upregu-
lated, possibly because AD169VarL lacks UL142. No differences
were observed between WT and DUS9-infected cells.
The US9-Mediated Downregulation of MICA*008
Resulted in Reduced NKG2D-Dependent NK Killing in
US9 Overexpression and during HCMV Infection
We next asked whether the US9-mediated reduction of
MICA*008 expression would affect NK-mediated killing. For
this purpose, we performed a killing assay in which 35S-labeled
cells expressing an EV or US9 were co-incubated for 5 hr with
primary bulk activated NK cells, in the presence and in the
absence of a blocking a-NKG2D monoclonal antibody (mAb)
(Figures 6A and 6B). We began with HCT116 cells, which only(D) FACS staining of FLS3HFF transducedwith an empty vector, MICA*004, orMIC
the indicated times after infection. Black histogram, UI cells; blue histogram, AD16
control staining. Representative of three independent experiments.
(E) The relative MFI of MICA for the 72 hpi staining in (D) was calculated as follows:
normalized according to the MFI of the UI control. Error bars show SEM for three
AD169varL-infected cells versus DUS9-infected cells. *p < 0.05. N.S., nonsignific
See also Figure S5.
Ceexpress full-length MICA alleles, and found no significant dif-
ferences between the killing of EV-expressing cells and US9-ex-
pressing cells (Figure 6A). When NKG2D was blocked, the killing
of HCT116 cells expressing US9 or EV was similarly reduced
(Figure 6A). In contrast, the MICA*008-homozygous 293T cells
expressing US9 were killed less efficiently than EV-expressing
cells in the absence of treatment or in the presence of a control
antibody (12E7; Figure 6B). Blocking of NKG2D eliminated these
differences, and the killing of all 293T cells was similar (Fig-
ure 6B), indicating the specific US9-induced abrogation of
MICA*008 expression resulted in reduced NKG2D-mediated
killing. It should be noted that NKG2D blocking significantly
reduced the killing even in US9-expressing 293T cells, presum-
ably because these cells express other stress-induced ligands
(Figure S1B).
We proceeded to test whether the increase in MICA*008 sur-
face expression in DUS9-infected cells would lead to increased
NK-mediated killing during HCMV infection. For this purpose,
we utilized FLS1 fibroblasts, which express full-length alleles,
and VH3 fibroblasts, which only express MICA*008. The fibro-
blasts were UI or infected with the WT AD169VarL virus or
with the DUS9 mutant. At 72 hpi, the 35S-labeled cells were
co-incubated overnight with primary bulk activated NK cells
(Figures 6C and 6D). The NK cells were left untreated, were
treated with a control mAb (12E7), or were treated with an
NKG2D-blocking mAb. FLS1 cells were poorly killed, and no
significant differences were observed in killing under all condi-
tions and treatments (Figure 6C). Importantly, there were no dif-
ferences between WT- and DUS9-infected cells under any
treatment. VH3 cells were also poorly killed; however, in
contrast to FLS1 cells, the killing was significantly higher in
the DUS9-infected cells compared with the WT-infected cells,
and this difference was abrogated when NKG2D was blocked
(Figure 6D).
We repeated this experiment in FLS3 HFF transduced with EV,
MICA*004-HA, or MICA*008-HA (Figures S6A–S6C). FLS3-EV
cells were poorly killed under all conditions (Figure S6A), but
transduction with MICA*004-HA and MICA*008-HA dramatically
increased killing efficiency. Blocking with a-NKG2D significantly
reduced the killing of MICA*004-HA and MICA*008-transfected
cells across all conditions (Figures S6B and S6C). In FLS3-
MICA*004-HA cells, HCMV infection significantly reduced the
killing, but no difference was observed between cells infected
with the WT virus or with the DUS9 mutant under any treatments
(Figure S6B). Importantly, in FLS3-MICA*008-HA cells, the killing
was significantly higher in the DUS9-infected fibroblasts com-
pared with the WT-infected fibroblasts, and NKG2D blocking
abrogated this difference (Figure S6C). These results indicate
that US9 is functional in reducing NKG2D-mediated killing during
HCMV infection.A*008 that were either UI or infected at anMOI of 2–4with the indicated virus at
9varL; red histogram,DUS9. Grey-filled histograms represent isotype-matched
background staining was subtracted, and then the MFI for each virus type was
independent experiments. A Student’s t test was used to compare the MFI of
ant.
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Figure 6. The US9-Mediated Reduction of
MICA*008 Leads to Reduced NKG2D-Medi-
ated Killing
(A and B) NK cells were untreated (squares),
incubated with a control mAb (12E7; circles) or with
a-NKG2D (triangles), and then incubated with
HCT116 cells in (A) or with 293T cells in (B). Black-
filled shapes indicate EV-expressing target cells,
and white-filled shapes indicate US9-expressing
target cells. Error bars represent SD. A Student’s t
test was performed to evaluate significance. *p <
0.05. N.S., nonsignificant. Representative of two
independent experiments.
(C and D) NK cells were untreated, incubated for
5 hr with a control mAb (12E7) or with a-NKG2D,
and then incubated overnight at an E:T ratio
of 150:1 with FLS1 HFFs in (C) or with VH3 HFFs
in (D).
Error bars represent SD. A Student’s t test was
performed to evaluate significance. *p < 0.05, **p <
0.01. N.S., nonsignificant. Representative of two
independent experiments. See also Figure S6.US9 Reduces the Amount of GPI-Anchored MICA*008
in HCMV-Infected Cells but Does Not Affect Overall
MICA*008 Levels
Finally, we asked whether US9 employs the same mechanism
during HCMV infection as in overexpression. To address this
question, we infected FLS3 transfectants with WT or DUS9
viruses at an MOI of 2–4 or left them UI. Cells were lysed at
72 hpi and analyzed by western blot (Figure 7A). Surpris-
ingly, despite large differences in the surface expression of
MICA*008 between WT and DUS9-infected cells, we saw no
differences in MICA*008 levels in the whole-cell lysates. Similar
results were obtained using FLS1 and VH3 HFFs (Figure 7B). In
VH3 HFFs, MICA*008 levels in whole-cell lysates were dramat-
ically increased compared with the UI control, both in WT and
in DUS9-infected cells. Notably, MICA*008 migrated at a lower
kDa (55 kDa) in the HCMV-infected cells compared with the
UI controls (60 kDa). We therefore subjected lysates from
FLS3 MICA*008-HA cells (Figure 7C, quantified in Figure 7D)
and from VH3 cells (Figure 7E, quantified in Figure 7F) to diges-
tion by endoH and PNGaseF. In UI cells of both kinds, the
34-kDa GPI-anchored endoH-resistant form of MICA*008 was
the most abundant. But following infection, the 37-kDa,
endoH-sensitive, non-GPI-anchored form of MICA*008 became
the most prevalent. The effect was especially pronounced in
VH3 cells where this form greatly accumulated (Figure 7E),
probably due to the upregulation of the endogenous
MICA*008 allele following HCMV infection. The 34-kDa GPI-
anchored form was reduced in the HCMV-infected cells, but
less so in the DUS9-infected cells. There was a 2- to 5-fold in-978 Cell Reports 10, 968–982, February 17, 2015 ª2015 The Authorscrease in the 34-kDa form of MICA (Fig-
ures 7D and 7F). Since the 34-kDa form
of MICA*008 is the form found at the cell
surface (Ashiru et al., 2013), this differ-
ence accounts for the decreased FACS
staining of MICA*008 in DUS9 versus
WT-infected cells (Figures 5B–5E).Since only a small proportion of the total quantity of MICA*008
seemed to be affected by US9, we could not analyze the effect of
proteasome inhibitors in the context of HCMV infection (data not
shown).
As it was apparent that a viral mechanism is inducing the accu-
mulation of MICA*008 in an endoH-sensitive form, which indi-
cates that MICA*008 is retained inside the ER, we sought to
verify this by immunofluorescence. UI, WT-infected, or DUS9-in-
fected FLS3-MICA*008-HA transfectants were fixed and stained
for MICA and for protein disulfide isomerase (PDI), an ERmarker,
at 72 hpi. The results showed a substantial merge between
MICA*008 and PDI both in WT and in DUS9-infected cells, corre-
sponding to a 2-fold increase in the correlation coefficient
between the two markers compared with UI controls (Fig-
ure S6D). This supports the conclusion that MICA*008 is retained
inside the ER during HCMV infection by a viral mechanism other
than US9.
DISCUSSION
The importance of the NKG2D ligands in HCMV immune control
has become increasingly clear in the past few years, with the dis-
covery of interlaced viral immune evasion mechanisms targeting
these ligands at multiple checkpoints. Because NKG2D is ex-
pressed both on NK and on CD8+ T cells, targeting its ligands
is doubly advantageous for the virus. Thesemechanisms parallel
in their complexity the HCMV mechanisms that target the MHC
pathways of antigen presentation at multiple stages: proteaso-
mal degradation of the MHC heavy chain (US2 and US11),
retention of MHC heavy chains in the ER (US3), and disruption of
peptide processing and transport to prevent peptide loading
(US6 and the viral miRNA miR-US4-1) (Halenius et al., 2014).
Similarly, at least four HCMV proteins, as well as a viral miRNA,
all act together to prevent NKG2D ligand expression, by means
which include protein sequestration, translational inhibition, and
protein degradation.
Against this wealth of diverse viral immune evasion mecha-
nisms, the existence of the ‘‘escape variant’’ MICA*008 was
seen as exemplifying the evolutionary process, which led to
the diversification of NKG2D ligands in the race against viruses
(Gonza´lez et al., 2008; Slavuljica et al., 2011). Our findings
show that this often-cited example is in fact only a piece of the
jigsaw. It is tempting to speculate that US9 specifically targets
this unique MICA allele and constitutes a viral adaptation to the
emergence of MICA*008. The specificity of US9 for MICA*008
and not for other MICA alleles illustrates its importance.
Here, we demonstrate that US9 targets MICA*008 to protea-
somal degradation, in a manner peculiarly reliant on MICA*008’s
maturation process. First, the quantity of ER-resident, non-GPI-
anchored MICA*008 is not substantially changed in US9-
expressing cells. This indicates that US9 does not target
MICA*008 as soon as it is synthesized. Instead, the kinetics of
US9’s effect on MICA*008 are slow, as shown by CHX chase,
mirroring MICA*008’s own slow maturation process (Ashiru
et al., 2013) and implying the US9 is dependent on a certain
lag in this process before it can act. US9’s dynamics vary from
those of US2 and US11, which act within minutes of MHC
heavy-chain synthesis (Loureiro and Ploegh, 2006). Finally,
US9 susceptibility requires specific features of MICA*008 that
are correlated with GPI anchoring status. At the same time,
GPI anchoring via the canonical pathway does not confer US9
susceptibility on MICA. Overall, these results indicate that it is
the nonstandard GPI-anchoring pathway of MICA*008 that is
required for US9’s activity. Involvement by constituents unique
to MICA*008’s nonstandard pathway would also account for
US9’s inability to target other canonically anchored stress-
induced ligands such as ULBP3.
The finding that US9 targets MICA*008 was very surprising
since HCMVwas considered ineffectual against this allele. There
are several possible explanations as for why the effect was not
noticed, most notably that MICA*008 downmodulation is less
efficient than that of the full-length alleles and might have been
overlooked. This is especially true in the study of native MICA al-
leles, which are concomitantly induced during infection, creating
the misleading appearance that no change has occurred com-
pared with UI controls. Another explanation is that only western
blots were used to assess HCMV’s effect on MICA, and this
method may not reveal US9’s effect, as we ourselves have
observed.
Although US9 efficiently reduces cellular MICA*008 levels in
overexpression settings, we could not observe such differences
during HCMV infection. There are two possible reasons for this
discrepancy: the first is that US9 acts by a different mechanism
during infection, sequestering MICA*008 in the ER rather than
degrading it. Although possible, we consider the second expla-
nation more plausible: that US9’s effect on MICA*008 overall
protein quantity is masked by an additional viral mechanism(s).CeSuch a masking effect is not uncommon when multiple proteins
act on the same target. For instance, the full effect of US18 and
US20 on MICA could only be demonstrated during infection by
deleting both of them (Fielding et al., 2014). Hence, it is not trivial
that we were able to demonstrate US9’s effect on MICA*008
even in the presence of these other viral mechanisms.
These mechanisms act at least in part by retaining MICA*008
in the ER, as shown by the accumulation of endoH-sensitive
MICA*008 and by its colocalization with an ER marker in
HCMV-infected cells. Taken together with our findings regarding
US9’s mechanism of action, we propose the following model for
HCMV’s effect on MICA*008 (Figure 7G): HCMV infection upre-
gulates the mRNA levels of MICA*008, resulting in increased
translation. To counter this upregulation, an unknown viral mech-
anism(s) binds the newly synthesized MICA*008 and sequesters
it inside the ER. Only MICA*008, which eludes these mecha-
nisms, undergoes GPI anchoring, via an unknown noncanonical
pathway. US9 targets this stage and diverts MICA*008 to the
cytosol, where it is subsequently degraded by the proteasome.
Thismodel postulates that, like the HCMVmechanisms targeting
MHC, the mechanisms that target MICA*008 also act on distinct
stages in its maturation. If these mechanisms act at an earlier
stage than US9 does, it would explain why US9 seems to affect
only a small proportion of MICA*008 in HCMV-infected cells, as
well as why US9’s effect was not completely masked by the
other viral mechanism(s).
Additional studies are required to elucidate this point. In partic-
ular, characterization of the unknown viral mechanism(s) and
study of US9’s function in their absence is required to settle the
question of US9’s mechanism of action during infection. Addi-
tional research is also required to shed light on additional aspects
of US9’s function, and in particular the role of MICA*008’s GPI-
anchoring pathway in it. Another open question is US9’s cellular
localization: studies, our own included,which foundUS9 to be ER
localized based on immunofluorescence and endoH sensitivity,
utilized US9 overexpression to determine its localization (Huber
et al., 2002). It is possible that in the context of HCMV infection
US9 reaches the plasma membrane, as shown by Weekes
et al. (2014) by mass spectrometry. If true, the meaning of this
altered localization pattern remains to be determined.
Although we have found that at least two viral mechanisms
target MICA*008, based on HCMV’s reduced ability to downre-
gulate MICA*008 compared with full-length alleles, we suggest
that the viral countermeasures targeting MICA*008 are still fewer
and/or less efficient than those targeting full-length alleles. While
the question of whether US18 andUS20 targetMICA*008 has yet
to be addressed, we speculate that they do not target this allele,
or do so with low efficiency. Overall, these findings support the
hypothesis that US9 is a recent addition to HCMV’s arsenal,
which has yet to fully adapt to the emergence of MICA*008.
Indeed, US9 is relatively new in CMV evolution: US9 is less
conserved than other US2–US11 family members that target
the MHC family (Pande et al., 2005) and less conserved than
the MICA-targeting proteins US18 and US20 (Fielding et al.,
2014), all of which have homologs in Rhesus CMV. Similarly,
MICA*008 has also evolved recently (Fukami-Kobayashi et al.,
2005). Furthermore, humans are the only species known to
encode a truncated allele of MICA (Pellet et al., 1999).ll Reports 10, 968–982, February 17, 2015 ª2015 The Authors 979
Figure 7. US9 Reduces the Amount of GPI-Anchored MICA*008 in HCMV-Infected Cells but Does Not Affect Overall MICA*008 Levels
(A) FLS3 HFFs transduced with an empty vector, MICA*004 or MICA*008, were either UI or infected at an MOI of 2–4 with the indicated virus and lysed 72 hpi.
Western blot was performed using a-MICA antibody. a-GAPDH served as loading control.
(B) FLS1 and VH3 HFFs were either UI or infected at an MOI of 2–4 with the indicated virus and lysed 72 hpi. Western blot was performed using a-MICA antibody.
a-GAPDH served as loading control.
(C) FLS3 HFF expressing MICA*008 were either UI or infected at an MOI of 2–4 with the indicated virus and lysed 72 hpi. The lysates were either untreated or
digested with endoglycosidase H or with PNGase F (marked N, H, and F, respectively). Western blot was performed using a-MICA antibody. a-Vinculin served as
loading control. Arrows indicate MICA forms with and without carbohydrates (CH+/).
(D) Quantification of the 34-kDa GPI-anchored form of MICA*008 shown in (C), normalized according to the loading control and then normalized relative to the
quantity in the UI control.
(legend continued on next page)
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We therefore propose the following event sequence: MICA
was initially targeted by HCMV proteins, such as UL142 and/or
US18 and US20. Subsequently, the truncated allele MICA*008
emerged and, due to its ability to escape HCMV control, con-
ferred a selective advantage and became very prevalent. As a
response, US9 arose to target MICA*008, perhaps as a duplica-
tion or adaptation of an ancestor US2–US11 familymember. This
example illustrates the dynamic and ongoing co-evolution of
virus and host, which enables the former to be so exquisitely
tailored to the latter.
EXPERIMENTAL PROCEDURES
Cells and Antibodies
The 293T (CRL-3216), RKO (CRL-2577), HeLa (CCL-2), A549 (CCL-185), and
MCC13 cell lines were used. All cell lines were obtained from the ATCC except
MCC13 cells, which were the kind gift of J.C. Becker (Medical University of
Graz, Austria). Human fibroblasts were obtained from primary cultures of fore-
skins from healthy donors. VH3 fibroblasts were described previously (Hengel
et al., 1995). FLS1 and FLS3 fibroblasts were the kind gifts of Professor F. Levi-
Schaffer (Hebrew University of Jerusalem). HFFs were used below passage
20. NK cells were isolated from peripheral blood lymphocytes (PBL) samples
and activated as previously described (Mandelboim et al., 1996). NK purity
was >95% by FACS analysis. All primary cells were obtained in accordance
with the institutional guidelines and permissions for using human tissues. Cul-
ture conditions and a list of antibodies used in this study appear in the Supple-
mental Experimental Procedures.
Lentiviral Constructs, Production, and Transduction
Lentiviruses were generated in 293T cells using a transient three-plasmid
transfection protocol as previously described (Stern-Ginossar et al., 2007).
Transduction efficiency was assessed by GFP or by surface expression, and
only cell populations with >90% efficiency were used for experiments. Where
necessary, limiting dilution or cell sorting was used. A detailed description of
primers and templates used for cloning and PCR mutagenesis is included in
the Supplemental Experimental Procedures.
Viruses
TheUS9 deletionmutant (DUS9) was generated using the BAC-cloned AD169-
varL genome pAD169 (Le et al., 2011) as parental. Details of mutant generation
and procedures for viral infection are described in the Supplemental Experi-
mental Procedures. The virus strain TB40/E-pp150-GFP was generously pro-
vided by C. Sinzger.
Cytotoxicity Assays and NK Cell Preparation
The cytotoxic activity of NK cells against various targets was assessed in 35S
release assays as described (Mandelboim et al., 1996) and incubated for
5 hr overnight. The final concentration of the blocking antibodies was 0.5–
1.0 mg per well. The spontaneous release in all assays was always less than
50% of the total release and is subtracted from the calculation of the percent-
ages of lysis. Percentages of killing were calculated as follows: (counts
per minute [CPM] sample  CPM spontaneous)/(CPM total  CPM sponta-
neous) 3 100.(E) VH3HFFs were UI or infected at anMOI of 2–4with the indicated virus and lysed
(marked N, H, and F, respectively). Western blot was performed using a-MICA. a-V
carbohydrates (CH+/).
(F) Quantification of the 34 kDa GPI-anchored form of MICA*008 shown in (E), n
quantity in the UI control.
(G) A model of HCMV effect on MICA*008: (1) following HCMV infection, MICA
(2) MICA*008’s immature, nonanchored form remains in the ER for a prolonge
(3) MICA*008, which has escaped other HCMVmechanisms, undergoesGPI anch
MICA*008 to the cytosol, where it is subsequently degraded by the proteasome.
See also Figure S6.
CeWestern Blot Analysis
Cells were plated at an equal density, incubated overnight, and lysed in buffer
containing 0.6% SDS and 10-mM Tris (pH 7.4). In certain cases, lysates were
digested with endoglycosidase H (endoH) or PNGaseF (NEB), according to the
manufacturer’s instructions. Quantification of blots was performed with the
Image Lab software.
qRT-PCR
Details of the qRT-PCR procedure and the list of primers are included in the
Supplemental Experimental Procedures.
Immunofluorescence
Cells were grown on glass slides and fixed and permeabilized in cold (20C)
methanol. Cells were blocked overnight in CAS-block (Life Technologies) and
then incubated overnight with primary antibodies diluted 1:50–200 in CAS
block; they were then washed and incubated overnight in secondary anti-
bodies diluted 1:500 in 5% BSA PBS. Cells were then washed, treated for
5min with DAPI, and coveredwith coverslips. A confocal laser scanningmicro-
scope (Olympus Fluoview FV1000) was used to obtain images. Co-localization
was calculated using the Olympus FluoView FV1000 software.
Flow Cytometry
For flow cytometry, cells were plated at equal densities and incubated over-
night. Resuspended cells were incubated on ice for 1 hr with the primary anti-
body at a concentration of 0.2 mg/well. The cells were then incubated for
30 min on ice with the appropriate secondary antibody at a concentration of
0.75 mg/well. In all experiments using cells transduced with a GFP-expressing
lentivirus, the histograms are gated on the GFP+ population.
Proteasome and Lysosome Inhibition and CHX Chase
For proteasome and lysosome inhibition, cells were incubated for 16 hr with
mock treatment or with the following inhibitors: EPX (Merck Millipore),
MG132 (Merck Millipore), BTZ (LC Biolabs), leupeptin (LEU; Merck Millipore),
or CCM A (Merck Millipore). For proteasomal and lysosomal inhibition during
CHX chase, cells were left untreated or were incubated for 8 hr in the presence
of CHX (50–100 mg/ml; Sigma-Aldrich) in combination with the aforementioned
inhibitors or with mock treatment. In all experiments, mock-treated cells were
treated with equivalent concentrations of DMSO or double-distilled water
(DDW).
PI-PLC Treatment
Cells were incubated for 2 hr with 2 U/ml phosphatidylinositol-specific phos-
pholipase C (PI-PLC; Sigma-Aldrich), and flow cytometry was performed as
described.
Statistical Methods
For statistical significance, Student’s t test analysis was used. A statistical test
was considered significant when p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.01.029.at 72 hpi. The lysates were untreated or digested with endoH or with PNGaseF
inculin served as loading control. Arrows indicate MICA formswith andwithout
ormalized according to the loading control and then normalized relative to the
*008 mRNA is upregulated and the protein is translated into the ER lumen.
d period, and unknown HCMV protein(s) bind and sequester it at this stage.
oring via an unknown noncanonical pathway. US9 targets this stage and diverts
Viral mechanisms are marked by red borders.
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